Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study

Yoshikazu Kinoshita, Yuuichi Sakurai, Nobuyoshi Takabayashi, Kentaro Kudou, Takahiro Araki, Takuya Miyagi, Katsuhiko Iwakiri, Kiyoshi Ashida, Yoshikazu Kinoshita, Yuuichi Sakurai, Nobuyoshi Takabayashi, Kentaro Kudou, Takahiro Araki, Takuya Miyagi, Katsuhiko Iwakiri, Kiyoshi Ashida

Abstract

Objectives: To assess the efficacy and safety of vonoprazan on heartburn symptoms in patients with nonerosive reflux disease (NERD) (ClinicalTrials.gov: NCT02954848).

Methods: This phase 3, double-blind, placebo-controlled study included Japanese patients aged 20 years and older with grade N/M NERD and recurrent heartburn. Patients received placebo (n = 245) or vonoprazan 10 mg (n = 238) for 4 weeks. The primary efficacy outcome was frequency of heartburn experienced by patients during the treatment period (proportion of days without heartburn). Other outcomes included cumulative improvement rates of heartburn, proportion of patients with complete heartburn resolution in the fourth week of treatment, and safety.

Results: Compared with placebo, the proportion of days without heartburn was not significantly higher in the vonoprazan group in the full analysis (primary end point, 72.55% vs 61.50%, vonoprazan vs placebo, P = 0.0643) but was significantly higher in the per-protocol-set sensitivity analysis (P = 0.0341). Early onset of response and significantly greater cumulative improvement rates of heartburn were observed in the vonoprazan group (P = 0.0003). In a post hoc analysis, a greater proportion of patients with complete heartburn resolution in the fourth week of treatment were reported in the vonoprazan group (P = 0.0023). Incidence of treatment-emergent adverse events was similar between treatment groups (23.5% vs 23.3%); most treatment-emergent adverse events were mild in severity.

Discussion: Although vonoprazan 10 mg was not superior to placebo with respect to proportion of days without heartburn in Japanese patients with NERD, vonoprazan had a significantly higher cumulative rate of heartburn resolution and was well tolerated.

Figures

Figure 1.
Figure 1.
Patient disposition. The full analysis and safety analysis sets were defined as all patients who were randomized and received at least 1 dose of the study drug. The per-protocol set was defined as all patients in the full analysis set who had available measurements for the primary variable, a prespecified minimal exposure to the treatment regimen, and no major protocol violations.
Figure 2.
Figure 2.
Cumulative improvement rate of heartburn during the treatment period in the full analysis set.
Figure 3.
Figure 3.
Histogram presenting proportion of days without symptoms of heartburn during the treatment period in the full analysis set.

References

    1. Ronkainen J, Aro P, Storskrubb T, et al. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population-the Kalixanda study. Aliment Pharmacol Ther 2006;23:1725–33.
    1. Wahlqvist P, Reilly MC, Barkun A. Systematic review: The impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther 2006;24:259–72.
    1. Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006;101:18–28.
    1. Vakil N, van Zanten SV, Kahrilas P, et al. ; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol 2006;101:1900–20.
    1. El-Serag HB. Epidemiology of non-erosive reflux disease. Digestion 2008;78(Suppl 1):6–10.
    1. Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol 2016;51:751–67.
    1. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): Comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007;41:131–7.
    1. Otake K, Sakurai Y, Nishida H, et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438). Adv Ther 2016;33:1140–57.
    1. Graham DY, Dore MP. Update on the use of vonoprazan: A competitive acid blocker. Gastroenterology 2018;154:462–6.
    1. Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: A phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp 2016;81–82:1–7.
    1. Hongo M. Minimal changes in reflux esophagitis: Red ones and white ones. J Gastroenterol 2006;41:95–9.
    1. . Phase 3 study of TAK-438 (10 mg) in the treatment of non-erosive gastroesophageal reflux disease. (). Accessed January 1, 2019.
    1. Hongo M, Hoshihara Y. Efficacy and safety of lansoprazole (AG-1749) 15 mg and 30 mg in Japanese patients with non-erosive reflux disease (NERD)—A phase III multicenter, double-blind, placebo-controlled trial. Jpn Pharmacol Ther 2008;36:655–71.
    1. Cremonini F, Ziogas DC, Chang HY, et al. Meta-analysis: The effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010;32:29–42.
    1. Asaoka D, Nagahara A, Hojo M, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep 2017;6:175–80.
    1. Niikura R, Yamada A, Hirata Y, et al. Efficacy of vonoprazan for gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease. Intern Med 2018;57:2443–50.
    1. Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: A multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2011;33:213–24.
    1. Uemura N, Inokuchi H, Serizawa H, et al. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol 2008;43:670–8.
    1. Tamura Y, Funaki Y, Izawa S, et al. Pathophysiology of functional heartburn based on Rome III criteria in Japanese patients. World J Gastroenterol 2015;21:5009–16.
    1. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016;43:240–51.
    1. Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: Randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 2018;67:1042–51.
    1. Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: Randomised phase 3 study. Gut 2018;67:1033–41.
    1. Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study. Gut 2016;65:1439–46.
    1. Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: Efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers–Results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther 2017;45:240–52.
    1. Kojima Y, Takeuchi T, Sanomura M, et al. Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective cross-sectional study. Digestion 2018;97:70–5.
    1. Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: A dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015;42:685–95.
    1. Sethi S, Richter JE. Diet and gastroesophageal reflux disease: Role in pathogenesis and management. Curr Opin Gastroenterol 2017;33:107–11.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다